Navigation Links
MetaStat Announces Stock Trading on OTC Bulletin Board
Date:11/14/2012

MONTCLAIR, N.J., Nov. 14, 2012 /PRNewswire/ -- MetaStat, Inc. ("MetaStat" or the "Company") (OTCBB: MTST), a life science company focused on the development and commercialization of proprietary clinical diagnostics that predict the probability of systemic hematogenous (blood borne) metastasis, as well as companion therapeutics to prevent this deadly spread, today announced that its common stock has been approved for quotation on the OTC Bulletin Board ("OTCBB") commencing with the start of trading on November 14, 2012.

Warren C. Lau, President and Chief Executive Officer of MetaStat, commented on the OTCBB listing, "We went through a diligent and thorough review process by FINRA to attain the Bulletin Board listing. We are extremely pleased to provide investors increased visibility and transparency that the Bulletin Board trading platform provides."

About MetaStat, Inc.
MetaStat was formed to allow cancer patients to benefit from the latest discoveries in how cancer spreads through the bloodstream to other organs in the body in a process called metastasis. Our mission is to become an industry leader in the emerging field of personalized cancer therapy. We intend to help clinicians better "customize" cancer treatment decisions by positively identifying high-risk patients who need aggressive therapy and by sparing low-risk patients from the harmful side effects and expense of chemotherapy and/or radiation therapies.  Additionally, we are developing companion therapeutics to work in conjunction with our diagnostic products.

We believe our MetaSite Breast™ and MenaCalc Breast™ diagnostic product lines will accurately predict the probability that breast cancer will systemically metastasize. Further, we believe our MenaCalc™ diagnostic platform may be applicable in up to 80% of all solid tumor cancers, including prostate, lung, colorectal, head and neck, and pancreatic.  As such, we believe our diagnostic products represent a significant breakthrough for cancer patients and their doctors because metastasis is responsible for 90% of fatalities from solid epithelial cancers. Most significantly, we believe our MenaBloc™ technology provides us with targets of intervention in key pathways for the development of therapeutics that may preemptively reduce or eliminate metastasis.

Our technology platform(s) and corresponding products are the result of over 15 years of collaboration involving four scientific/academic institutions. We believe we are unique and differentiated in the marketplace because our discoveries are based on direct microscopic visualization of living, functioning tumors in vivo and we have the ability to specifically isolate and thus characterize the behavior, genetics and mechanics of these highly metastatic cells as they migrate to and penetrate blood vessels, where they are subsequently carried away to establish distant site tumors.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Contact:
For More Information,
Warren C. Lau
President & CEO
MetaStat, Inc.
(832) 758-7488
warren@metastat.com


'/>"/>
SOURCE MetaStat, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
2. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
3. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
4. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
5. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
6. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
7. MetaStat, Inc. Executes Two New Licenses
8. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
9. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
10. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Enhanced Biosimilars and Personalized Medicine Initiatives for its Clients
11. Comprehensive Care Corporation Announces Profitable Nine Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 Shire plc ... Jeff Poulton , Chief Financial Officer, will present at the ... Boston, MA on Wednesday, May 04, 2016, 10:00 ... will be available on the Presentations and Webcasts section of ... of the webcast will be available on this same website ...
(Date:4/27/2016)... 27, 2016 Oasmia Pharmaceutical ... of a new generation of drugs within human ... results for Paclical/Apealea in the Phase III study ... epithelial ovarian cancer. These preliminary results showed non-inferiority ... with carboplatin versus Taxol in combination with carboplatin. ...
(Date:4/27/2016)... 2016 The global  gamma ... billion by 2022, according to a new report ... towards a healthy lifestyle is expected to drive ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... health treatment expenditure has urged consumers to switch ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Create an ... users can distort and manipulate three-dimensional shapes with ease all within Apple ... point, lines, polygons, polygon texture animation, opacity texture animation, overall shape texture displacement, ...
(Date:4/30/2016)... , ... April 30, 2016 , ... ... announced RANKED Health , a program to critically evaluate and rank health-focused ... of the program is to provide independent, unbiased and accurate information to help ...
(Date:4/30/2016)... ... April 30, 2016 , ... Dr. Trevor ... of EMED, today signed a multifaceted agreement which will allow for the research ... University Department of Natural and Applied Sciences, Allied Health and Nursing will work ...
(Date:4/30/2016)... Rosa, CA (PRWEB) , ... April 30, 2016 , ... “Aging well is a challenge for all of us, but ... NCMA’s Dr. Parul T. Kohli . “Research is showing more and more that there ... risk of disease and disability as we age.” Top priorities Dr. Kohli’s recommends for her patients ...
(Date:4/29/2016)... Miami, FL (PRWEB) , ... April 30, 2016 ... ... manufacturer and engineer of patented products, announces the Pick Up Springboard, an automotive ... SUV and Light Truck Manufacturing industry is worth $162 billion," says Scott Cooper, ...
Breaking Medicine News(10 mins):